# The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

> **NCT04991311** · PHASE3 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 12 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** Glepaglutide

## Key facts

- **NCT ID:** NCT04991311
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-10
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-09-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991311, "The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04991311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*